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Abstract
Background: Hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome (LS) account for a
significant proportion of inherited gynecologic malignancies, mainly caused by pathogenic germline mutations in
the BRCA1 and BRCA2 genes or in mismatch repair (MMR) genes, such as MLH1 and MSH2. Women harboring
deleterious mutations in these genes have increased life-time risks of developing a number of malignancies
including ovarian cancer. Since there is a phenotypic overlap of HBOC and LS, timely identification of individuals
at-risk of a particular syndrome is crucial in order to optimize cancer risk management.
Case presentation: We report a novel pathogenic MSH2 mutation, c.2656G > T, which was identified in a 67-
year-old female patient with breast cancer, who had previously tested negative for a deleterious mutation in the
breast cancer susceptibility genes BRCA1, BRCA2, CHEK2 or RAD51C. The patient reported a personal history of
endometrial cancer diagnosed at age 48, and a strong family history of breast and ovarian cancer, as well as
several other malignancies within the spectrum of LS. The novel mutation was also found in the index patient’s
daughter and a niece, who were diagnosed with endometrial and ovarian cancer, respectively. Breast and
endometrial tumors from c.2656G > T mutation carriers showed loss of MSH2 and MSH6 protein expression. The
mutation was absent in the control population.
Conclusions: Our finding suggests that testing for MMR genes may be of benefit to BRCA1/2 negative families
with overlapping HBOC and LS phenotype in Pakistan. It is clinically significant to identify individuals harboring
mutations in genes linked with a particular syndrome so that they can benefit from targeted life-saving cancer
surveillance and preventive strategies.
Keywords: HNPCC, LS, MSH2, Endometrial cancer, Hereditary breast and ovarian cancer, Pakistan
* Correspondence: usmanr@skm.org.pk
1Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and
Research Centre (SKMCH & RC), Lahore, Pakistan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rashid et al. Hereditary Cancer in Clinical Practice  (2016) 14:14 
DOI 10.1186/s13053-016-0056-3
Background
Genetic testing for hereditary cancer has become an es-
sential part of modern oncologic practice. It is offered to
individuals with strong personal and/or family histories
of cancer(s). The two most common cancer syndromes
with autosomal dominant inheritance among women
with gynecologic malignancies include hereditary breast
and ovarian cancer (HBOC) and Lynch syndrome (LS;
also known as hereditary non-polyposis colorectal can-
cer (HNPCC)). HBOC is mainly caused by germline mu-
tations in the BRCA1 and BRCA2 genes [1], while LS is
due to mutations in mismatch repair (MMR) genes in-
cluding MLH1, MSH2, MSH6 and PMS2 [2]. Individuals
carrying BRCA1/2 mutations face high lifetime risks of
breast and ovarian cancer [3]. Individuals with mutations
in MMR genes have increased lifetime risks of develop-
ing colorectal, endometrial, and ovarian cancers [4–11].
Ovarian cancer is seen in both syndromes. The lifetime
risks of developing breast cancer [12–16] or endomet-
rial/colorectal carcinoma [17, 18] have also been re-
ported to be elevated among LS- or HBOC-associated
mutation carriers, respectively. Hence, there is a possible
phenotypic overlap of these syndromes, which makes
genetic counseling, screening, preventive and therapeutic
decisions more challenging as diverse cancer risk man-
agement strategies are offered to individuals affected by
HBOC or LS. Appropriate identification of individuals
carrying mutations in a particular gene is an important
factor in optimizing cancer risk management.
Two families, one from Italy and the other from
Canada, with features of HBOC and LS have previously
been described [19, 20]. In both reports double heterozy-
gotes for BRCA1/2 and MLH1/MSH2 mutations were
identified. Here, we report the identification of a novel
single (heterozygous) deleterious c.2656G > T MSH2
mutation in a BRCA1/2 negative Pakistani family within
the spectrum of HBOC and LS.
Case presentation
A 67-year-old Pakistani woman of Pathan ethnicity pre-
sented with a lump in the left breast to the SKMCH &
RC, Lahore, Pakistan, in October 2008. Excision biopsy
revealed a grade 3 invasive ductal breast carcinoma
measuring 2.8 cm in its greatest dimension (pT2) with-
out evidence of lymph node involvement (pN0). Immu-
nohistochemical (IHC) analyses showed that the tumor
was negative for estrogen receptor (ER), progesterone re-
ceptor (PR), human epidermal growth factor receptor 2
(HER-2), MSH2 and MSH6 expression. She reported a
prior diagnosis of endometrial carcinoma at age 48, for
which she had undergone a total abdominal hysterec-
tomy and bilateral salpingo-oophorectomy. In the adju-
vant setting, she had received radiotherapy at University
College Hospital, London, UK.
The index patient (III:14) reported an extensive family
history of malignancy (Fig. 1). Her sister (III:12), cousin
(III:1), and niece (IV:1) were diagnosed with unilateral
breast cancer. Another sister (III:10) was diagnosed with
bilateral breast cancer. Additionally, six family members
had presented with gynecologic malignancies; one sister
(III:18) and two nieces (IV:17, IV:20) presented with
ovarian cancer; her daughter (IV:23) and two nieces
(IV:4, IV:16) were diagnosed with endometrial cancer.
Another sister (III:5) and one maternal cousin (III:4) had
previously been diagnosed with intestinal cancer, and
three descendants (IV:1, IV:3, IV:4) of that sister were af-
fected by colon cancer. The index patient reported sev-
eral other family members with various malignancies
including her mother (II:6) with liver cancer, a brother
(III:8) with stomach cancer, one nephew (IV:13) with
renal cancer and another (IV:8) with prostate cancer,
and one niece (IV:22), one grandniece (V:1) and one
grandnephew (V:2) with childhood malignancies includ-
ing brain tumor, osteoblastoma and leukemia, respect-
ively. The cancer diagnoses of the index patient (III:14),
her daughter (IV:23) and one niece (IV:20) were con-
firmed by review of medical records and/or pathological
reports. All other cancer diagnoses were self-reported or
reported by other family members.
Given the strong family history of cancer, the patient
was referred to SKMCH & RC for genetic counseling
and risk assessment and was enrolled in the study after
obtaining written informed consent. The study was ap-
proved by the ethical review board of SKMCH & RC.
Due to the presence of multiple breast and ovarian can-
cers in this family, the preliminary diagnosis was HBOC
syndrome [1]. The patient had previously tested negative
for deleterious small-range BRCA1/2 mutations and
large genomic rearrangements (M. U. Rashid, unpub-
lished data) using denaturing high performance liquid
chromatography (DHPLC) analysis followed by DNA se-
quence analysis of variant fragments and multiplex
ligation-dependent probe amplification (MLPA) as de-
scribed [21, 22]. The patient had also tested negative for
mutations in CHEK2 [23] and RAD51C [24], implying
the involvement of other gene(s) contributing to disease
risk in this family.
This family also fulfilled the recognized criteria for
suspected LS [25] (Fig. 1): that includes (i) among
first degree relatives of a colorectal cancer patient (or
in himself ) at least 1 colorectal cancer, cancer of the
endometrium, small bowel or urinary tract; (ii) at
least one of the above cancers diagnosed under age
50; and (iii) familial adenomatous polyposis excluded
[25]. The index case was screened for germline muta-
tions in the MLH1, MSH2 and MSH6 genes using
DHPLC and DNA sequence analysis as described
elsewhere [26]. A novel disease-causative heterozygous
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nonsense mutation in exon 16 of MSH2, c.2656G > T
(p.Glu886*), was identified.
Genetic MSH2 testing was offered to other affected
family members. The mutation was also detected in the
index patient’s daughter (IV:23) who was diagnosed
with endometrial cancer, and one niece (IV:20) affected
by ovarian cancer. Her nephew (IV:8), who was diag-
nosed with prostate cancer, tested negative for this mu-
tation. The mutation was also not identified in 100
healthy female controls.
Discussion
We report the identification of a deleterious MSH2
germline mutation in a Pakistani family with a strong
family history of malignancy (6 breast cancers, 3 ovarian
cancers, 4 endometrial carcinomas, 3 colon cancers, 2
intestinal cancers) within the spectrum of HBOC and
LS, who tested negative for BRCA1/2 mutations. Our
data highlight the clinical implications of this finding,
specifically with respect to genetic counseling, screening,
and prophylaxis of mutation carriers in such families.
The index patient harboring the MSH2 mutation was
affected by endometrial cancer at age 48 and breast can-
cer at age 67. The occurrence of breast cancer following
endometrial cancer is in line with data from Win and
colleagues, who showed that women with LS have an in-
creased risk of breast cancer after endometrial cancer
[27]. The mutation, c.2656G > T (p.Glu886*), located in
exon 16 of the MSH2 gene, is novel and has not been
previously reported in several large variant databases
(Exome Aggregation Consortium (ExAC), http://exac.
broadinstitute.org/; Exome Sequence Project (ESP),
http://evs.gs.washington.edu/EVS/; Human Gene Muta-
tion Database (HGMD), http://www.hgmd.cf.ac.uk/ac/
index.php); Leiden Open Variation Database (LOVD),
http://chromium.liacs.nl/LOVD2/colon_cancer/, Mis-
match Repair Genes Variant Database (MMRGVD),
http://www.med.mun.ca/mmrvariants/ or Universal Mu-
tation Database (UMD), http://www.umd.be/ (by May
2016). It is likely to be pathogenic as it generates a pre-
mature termination codon resulting in a truncated pro-
tein, with loss of 49 C-terminal amino acid residues, a
region involved in MSH2 homodimer formation and
MSH3/MSH6 interaction [28]. The location of the muta-
tion is in a region of high sequence conservation among
humans, grivets, mice and cows and it’s absence in 100
healthy controls suggests that it is associated with the
disease. Several other pathogenic mutations in this re-
gion have previously been described [29, 30] (LOVD,
http://chromium.liacs.nl/LOVD2/colon_cancer/; UMD
database http://www.umd.be/). Moreover, the c.2656G >
T mutation segregated with the disease as it was identi-
fied in the index patient’s daughter, who had herself suf-
fered from endometrial cancer at age 52 and in a niece
Fig. 1 Pedigree and MSH2 c.2656 G > T (p.Glu886*) carriers of the Pakistani cancer family 326. Circles are females, squares are males, and a diagonal
slash indicates a deceased individual. Symbols with filled left upper quadrant: unilateral breast cancer. Symbols with filled upper half: bilateral breast
cancer. Symbols with filled left lower quadrant: ovarian cancer. Symbols with filled right lower quadrant: cancer other than breast/ovarian cancer, the
name of which is mentioned. Identification numbers of individuals are shown below the symbols. The index patient is indicated by an arrow. ALL,
acute lymphoid leukemia; BC, breast cancer; OC, ovarian cancer. The numbers following these abbreviations indicate age at cancer diagnosis. M+,
mutation positive. [M+], obligatory mutation carrier. M-, mutation negative
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affected by ovarian cancer at age 43. The latter probably
inherited the mutation from her deceased mother, who
had been diagnosed with breast cancer at age 58, sug-
gesting that this mutation may predispose to breast can-
cer. Association of MMR gene mutations with breast
cancer has previously been observed in various studies
among Australian, Brazilian, Danish, Dutch, and US popu-
lations [12–16]. Recently, a four-fold increase in breast
cancer risk was reported in MMR gene mutation carriers
from Australia, New Zealand, Canada, and the United
States compared to the general population [31]. In con-
trast, initial studies among Finnish and US populations
showed no association [4, 32]. The variation in observed
data may be due to population heterogeneity or involve-
ment of other genetic and/or non-genetic risk factors.
The breast tumor associated with the pathogenic
MSH2 mutation in our index patient was negative for
ER, PR and HER2 expression, also known as triple-
negative breast cancer (TNBC). This observation is in
agreement with previous findings that breast tumors
linked with mutations in MMR genes are primarily nega-
tive for ER and PR expression [33]. However, BRCA1 as-
sociated breast tumors are also reported to significantly
display TNBC [34], so that TNBC phenotype cannot be
utilized to distinguish between BRCA1 and MMR gene
mutation carriers. The index patient’s breast tumor was
also negative for MSH2 and MSH6 protein expression
(data not shown). This finding suggests that the MSH2
germline mutation, in addition to endometrial cancer,
may also predispose to breast cancer in this family.
Given the controversy as to whether breast cancer is a
part of LS or not, in the literature, large prospective
studies will help to clarify this issue.
Patients with LS have increased lifetime risks of devel-
oping ovarian, endometrial, and colorectal cancers, ran-
ging from 6.7–13.5 %, 31.5–62 %, and 50–80 %,
respectively [4–6, 9, 11]. In the family reported here, the
MSH2 mutation was found to co-segregate with ovarian
and endometrial cancer. We were unable to study co-
segregation of this mutation in the colon/intestinal cancer
cases, since they were either deceased or did not agree to
participate in this study. The mean age of colon/intestinal
cancer diagnosis in this family was 48.8 years, which is
similar to the mean age of 44.8 years previously reported
in Caucasians withMSH2 mutations [35].
Previously, bi-allelic germline mutations in MMR genes
have been reported with a rare constitutional MMR-
deficiency syndrome, characterised by a broad spectrum
of childhood onset malignancies mostly among individuals
with a history of parental consangunity [36, 37]. Among
children with this syndrome, MSH2 mutations are less
common, while PMS2 mutations are most commonly
found [37]. Three paediatric cancers (leukemia, brain
tumor, and osteoblastoma) were also observed in our
study, with unknown parental consanguinity status. Due
to the lack of DNA samples, none of these individuals
(IV:22, V:1 and V:2) nor their parents (III:13, IV:21, IV:26
and IV:27) could be tested. It is unlikely that the child-
hood malignancies in the Pakistani family are linked with
the MSH2 mutation, as manifestations of LS in the par-
ents of these children were not observed. Hence, the role
of PMS2 or other genes known to be involved in these
childhood malignancies cannot be excluded.
Different sets of clinical criteria for identifying patients
at high risk of LS include the stringent Amsterdam I/II
criteria [38, 39], which are based on a family history of
at least three relatives with histologically verified colo-
rectal cancer/cancers linked with LS, respectively, and
the less stringent Bethesda guidelines, later updated to
the revised Bethesda guidelines [40, 41]. The revised Be-
thesda guidelines, based on clinicopathologic parame-
ters, have been developed to identify high-risk patients
by evaluation of microsatellite instability (MSI) and/or
IHC testing of their tumors. Unfortunately, this strategy
could not be applied to the Pakistani index patient due
to restraints of normal/tumor tissue. However, the Paki-
stani family fulfilled the less stringent criteria of sus-
pected LS [25], which is based on a family history of
only two LS-linked cancers. Our finding support the no-
tion that the suspected LS criteria may be useful for the
identification of Pakistani families [25, 42, 43].
To our knowledge, this is the first Asian family with a
history of cancer within the spectrum of HBOC and LS,
in which a novel, single heterozygous mutation in a
MMR gene was identified. Different findings have been
reported in two other studies among two families, one
from Italy and another from Canada, which have a simi-
lar phenotype, but different genotypes, with double het-
erozygous BRCA1/2 and MMR gene mutations, were
identified [19, 20], which may confer an altered risk.
Women with double heterozygous BRCA1/2 and MMR
gene mutations were younger at time of diagnosis of
breast cancer (range 32–46) than the single heterozy-
gous Pakistani patient(s) (ages: 58 (obligatory carrier),
67) described in this report. The Pakistani patient did
not harbor a deleterious mutation in BRCA1/2 and also
tested negative for mutations in CHEK2 [23], RAD51C
[24], and PALB2 (M. U. Rashid, unpublished data). We
cannot exclude the possibility that a mutation in yet
another breast cancer susceptibility gene exists, which
was not analyzed. While the mean age of breast cancer
diagnosis in the Pakistani population is 47 years (range
18–90) [44], Pakistani patients with BRCA1, CHEK2,
or RAD51C mutations presented with breast cancer at
a mean age of 31 years (range 22–49), 41.5 years
(range 30–53), and 50 years (range 49–51), respectively
[21, 23, 24]. In the current pedigree, the mean age of
breast cancer onset of 65.7 years (range 58–76) was
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higher, suggesting the involvement of other susceptibil-
ity gene(s). The deleterious mutation in the MSH2
gene reported here may predispose to breast cancer in
this family, since it was detected in one family member
diagnosed with breast cancer at age 67, while another
family member diagnosed with breast cancer at age 58
is likely to be an obligatory carrier, who passed the
mutation on to her daughter. The co-segregation of
the mutation with breast cancer could not be investi-
gated further, because two relatives were deceased and
another refused to participate. Therefore it may still be
possible that the overrepresentation of breast cancer in
this family is by chance, considering that breast cancer
is the most common invasive malignancy in Pakistani
women (Globocan 2012; http://globocan.iarc.fr/).
Conclusions
Our findings suggest thatMMR gene testing may be bene-
ficial to BRCA1/2 negative families presenting with clinical
features and a pedigree chart suggestive of HBOC syn-
drome, especially if they report other LS-associated can-
cer(s). It is clinically important to identify individuals with
LS, so that they can benefit from targeted life-saving can-
cer surveillance strategies.
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